At a glance
ClinicalIndex Comparison RecordN/ACompleted· 107 enrolled
Drug / intervention
InnFocus MicroShunt implantationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Market Study to Evaluate Safety and Effectiveness of the InnFocus Microshunt™ (MIDI Arrow) in Patients With Primary Open Angle Glaucoma
In Brief
A clinical study evaluating InnFocus MicroShunt implantation for Primary Open Angle Glaucoma. Completed, enrolled 107 participants across 6 sites in 4 countries.
Detailed Summary
Prospective, multicentric, single arm post market study to gather safety and effectiveness data on the CE Marked InnFocus MicroShunt (MIDI Arrow) device in primary open angle glaucoma patients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPrimary Open Angle Glaucoma
CountriesFrance, Netherlands, Spain, Switzerland
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedJun 2014
Primary CompletionNov 2017
TodayJul 2026
First PostedJun 27, 2014
Enrollment StartApr 4, 2014
Primary CompletionNov 27, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.0 years ago
Interventions
InnFocus MicroShunt implantationdevice
Implantation will include the use of Mitomycin C applied with sponges.